Damora Therapeutics director Andrew Cheng files initial beneficial ownership statement
DMRA•Initial Form 3 filing
- Damora Therapeutics director Andrew Cheng filed an initial Form 3 on Aug. 13, 2026.*
Related News
Oncotelic net loss widens to $1.9 million in Q2 FY26; revenue totals $250,000
OTLC•
Cellebrite names Shiven Ramji CEO, replacing Thomas Hogan
CLBT•
Telomir net loss narrows to $1.72 million in Q2 FY26; revenue flat at no revenue
TELO•
Alpex Acquisition Q2 net loss widens to $123,388
ALPX•
Constellation Energy director Roger W. Crandall buys 1,500 shares worth $417,931
CEG•